Get the Stockscreener App
18.75
33.36%
4.69
After Hours:
18.11
-0.64
-3.41%
Viridian Therapeutics Inc stock is traded at $18.75, with a volume of 16.11M.
It is up +33.36% in the last 24 hours and down -0.48% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
See More
Previous Close:
$14.06
Open:
$19.07
24h Volume:
16.11M
Relative Volume:
6.96
Market Cap:
$1.93B
Revenue:
$70.85M
Net Income/Loss:
$-324.22M
P/E Ratio:
-4.9258
EPS:
-3.8065
Net Cash Flow:
$-277.36M
1W Performance:
+37.77%
1M Performance:
-0.48%
6M Performance:
-23.22%
1Y Performance:
+42.91%
1-Day Range:
$17.42
$20.00
1-Week Range:
$13.18
$20.00
52-Week Range:
$11.76
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.75 | 1.45B | 70.85M | -324.22M | -277.36M | -3.8065 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Reiterated | Wedbush | Outperform |
| Dec-03-25 | Initiated | William Blair | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian (VRDN) Climbs 33% on Looming Drug Commercialization - Insider Monkey
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Viridian’s Reveal-2 beats expectations with elegrobart in TED - BioWorld News
Viridian soars on top-line phase 3 data for elegrobart in thyroid eye disease - Seeking Alpha
Viridian Therapeutics launches $250 million capital raise - Investing.com
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock - Business Wire
Viridian eye disease drug surpasses expectations in late-stage trial; shares soar - Reuters
Jefferies raises Viridian Therapeutic stock price target on trial data - Investing.com
VRDN: Veligrotug and elegrobart show strong efficacy in TED, with launch readiness and pipeline expansion - TradingView
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress - BioSpace
Positive top-line Phase III results for Viridian’s elegrobart - The Pharma Letter
Viridian Therapeutics : REVEAL-2 Phase 3 Topline Results (Presentation) - marketscreener.com
Viridian’s elegrobart meets primary endpoint in chronic TED trial - Investing.com UK
PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results - Yahoo Finance
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market - Benzinga
VRDN Stock Reassessed As Analysts Cut Targets But Stay Bullish - timothysykes.com
Viridian Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Viridian Therapeutics stock surges on positive trial results By Investing.com - Investing.com Canada
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease - TipRanks
MSN Money - MSN
Elegrobart boosts Viridian (NASDAQ: VRDN) with strong Phase 3 TED trial win - Stock Titan
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q1 Revenue $141,000 - marketscreener.com
Viridian Therapeutics (VRDN) deepens Q1 loss as late‑stage TED drugs progress - Stock Titan
Viridian (NASDAQ: VRDN) posts Q1 loss and advances TED drug approvals - Stock Titan
BRIEF-Viridian Therapeutics Q1 Revenue USD 6 Thousand Vs. IBES Estimate USD 27.5 Thousand - TradingView
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Why (VRDN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Jennison Associates LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Pictet Asset Management Holding SA Sells 126,618 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN
VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal? - MSN
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN) - Insider Monkey
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease - MSN
CapEx per share of Viridian Therapeutics, Inc. – FWB:1S1 - TradingView
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - AOL.com
Understanding Momentum Shifts in (VRDN) - Stock Traders Daily
Kopp Family Office Sells 117878 Shares of Viridian Therapeutics - HarianBasis.co
Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year - Insider Monkey
Truist Adjusts Viridian Therapeutics Price Target Amid Sector Shifts - HarianBasis.co
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - The Motley Fool
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
VRDN Maintained by Truist Securities -- Price Target Lowered to $33 - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $33.00 by Analysts at Truist Financial - MarketBeat
Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026 - simplywall.st
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% - Yahoo Finance
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):